What is skeletal hyperostosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Skeletal Hyperostosis?

Skeletal hyperostosis is a condition characterized by abnormal bone overgrowth, most commonly manifesting as diffuse idiopathic skeletal hyperostosis (DISH), which involves calcification and ossification of ligaments and entheses (tendon/ligament insertion sites), particularly along the spine. 1

Key Pathological Features

DISH specifically involves "flowing" ossification along the anterolateral margins of at least four contiguous vertebrae, distinguishing it from degenerative spondylosis or spondyloarthropathy. 2 The condition represents systemic calcification of soft tissues, predominantly affecting:

  • Spinal ligaments (especially thoracic spine on the right side)
  • Entheses throughout the body
  • Intervertebral disc spaces
  • Sternocostal articulations 3

The ossification creates bridging bone formations that progressively stiffen the spine and can extend to extraspinal sites. 1

Clinical Presentation and Demographics

DISH most commonly affects men over 50 years of age and is observed across all continents and races. 1 While many patients remain asymptomatic, symptomatic presentations include:

  • Back pain and spinal stiffness 2
  • Reduced range of articular motion 1
  • Dysphagia (difficulty swallowing) from cervical involvement 2
  • Cervical myelopathy and lumbar stenosis 2

A critical pitfall: DISH dramatically increases the risk of unstable spinal fractures from even minor trauma (such as ground-level falls), as the rigid, osteoporotic spine becomes vulnerable to injury. 4, 2 Diagnosis of these fractures is often delayed because patients have baseline spinal pain and the inciting trauma may be trivial. 2

Drug-Induced Skeletal Hyperostosis

Long-term systemic retinoid therapy (etretinate, acitretin, isotretinoin) can cause skeletal hyperostosis as an adverse effect, particularly with 2-4 years of treatment. 5 This manifests as:

  • Extraspinal tendon and ligament calcification (ankles, pelvis, knees most common) 5
  • DISH-like spinal involvement with degenerative spondylosis and syndesmophytes 5
  • Bone exostoses 5

In children, retinoid-induced hyperostosis can include premature epiphyseal closure, periosteal thickening, and extraosseous calcification, though this appears dose-dependent and linked to high doses (up to 3.5 mg/kg) used for months to years. 5 Recent British Association of Dermatologists guidelines note that routine radiographic monitoring is not recommended for long-term acitretin therapy, as evidence does not support this practice and exposes patients to unnecessary radiation; targeted X-rays should be reserved for atypical musculoskeletal pain. 5

Pathophysiology

The etiology remains poorly understood, but DISH is often an indicator of underlying metabolic disease, with associations to:

  • Hyperinsulinemia with or without hyperglycemia
  • Hypertension
  • Hyperlipidemia
  • Hyperuricemia 6

Recent research implicates disrupted purine metabolism and pyrophosphate homeostasis in the development of ectopic mineralization, with loss of equilibrative nucleoside transporter 1 (ENT1) producing DISH-like lesions in animal models. 3

Distinction from Other Conditions

Skeletal hyperostosis differs from primary osteoarthritis in prevalence patterns, gender distribution, anatomical sites of involvement, and the magnitude and distribution of spinal and peripheral joint changes. 6 The formal diagnosis requires multiple contiguous fully formed bridging ossifications, which likely represent advanced disease stages. 1

References

Research

Diffuse idiopathic skeletal hyperostosis: musculoskeletal manifestations.

The Journal of the American Academy of Orthopaedic Surgeons, 2001

Research

Loss of equilibrative nucleoside transporter 1 in mice leads to progressive ectopic mineralization of spinal tissues resembling diffuse idiopathic skeletal hyperostosis in humans.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.